Yahoo
NasdaqCM - Nasdaq Real Time Price USD

KORU Medical Systems, Inc. (KRMD)

3.0550 +0.0050 (+0.16%)
As of 9:36:18 AM EST. Market Open.
Trade KRMD on Coinbase
Chart Range Bar
Loading chart for KRMD
  • Previous Close 3.0500
  • Open 3.0500
  • Bid 2.1600 x 200
  • Ask 4.0100 x 200
  • Day's Range 3.0500 - 3.0550
  • 52 Week Range 2.8600 - 6.6080
  • Volume 1,103
  • Avg. Volume 243,029
  • Market Cap (intraday) 140.325M
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0400
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 6.25
  • Motley Fool Rating Bullish

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

www.korumedical.com

73

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KRMD
47.42%
S&P 500 (^GSPC)
10.46%

1-Year Return

KRMD
20.44%
S&P 500 (^GSPC)
10.36%

3-Year Return

KRMD
37.00%
S&P 500 (^GSPC)
73.50%

5-Year Return

KRMD
5.71%
S&P 500 (^GSPC)
62.25%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 12.05M
Earnings 252.45k
Profit Margin 2.10%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5M
10M
-6.0%
-4.0%
-2.0%
0.0%
2.0%

Analyst Insights

View More

Analyst Price Targets

5.00
6.25 Average
3.0550 Current
8.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/13/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Maintains
Price Target 6 -> 6

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.03%

  • Return on Assets (ttm)

    -3.86%

  • Return on Equity (ttm)

    -10.52%

  • Revenue (ttm)

    45.11M

  • Net Income Avi to Common (ttm)

    -1.82M

  • Diluted EPS (ttm)

    -0.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.29M

  • Total Debt/Equity (mrq)

    18.33%

  • Levered Free Cash Flow (ttm)

    725.83k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: